These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21702117)

  • 1. [Treatment of chronic myeloid leukemia with imatinib].
    Ohnishi K
    Gan To Kagaku Ryoho; 2011 May; 38(5):746-8. PubMed ID: 21702117
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib in chronic myeloid leukemia.
    Krause SW; Holler E
    N Engl J Med; 2007 Apr; 356(17):1780; author reply 1780. PubMed ID: 17460235
    [No Abstract]   [Full Text] [Related]  

  • 3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
    Smith BD
    J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
    [No Abstract]   [Full Text] [Related]  

  • 5. [Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia].
    Nielsen JL
    Ugeskr Laeger; 2003 May; 165(20):2111. PubMed ID: 12812107
    [No Abstract]   [Full Text] [Related]  

  • 6. How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
    Hasford J; Pfirrmann M; Hochhaus A
    Leukemia; 2005 Apr; 19(4):497-9. PubMed ID: 15861176
    [No Abstract]   [Full Text] [Related]  

  • 7. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Imatinib. An anticancer agents indicated in the treatment of chronic myeloid leukemia]].
    Taéron C
    Rev Infirm; 2004 Feb; (98):39-40. PubMed ID: 15042992
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of chronic myeloid leukemia with imatinib. A case of translational medicine].
    Dosne Pasqualini C
    Medicina (B Aires); 2010; 70(3):293-6. PubMed ID: 20529782
    [No Abstract]   [Full Text] [Related]  

  • 10. [Management of chronic myeloid leukemia by imatinib].
    Kizaki M
    Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
    [No Abstract]   [Full Text] [Related]  

  • 11. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
    Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
    Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
    [No Abstract]   [Full Text] [Related]  

  • 12. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 14. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.
    Lucas CM; Wang L; Austin GM; Knight K; Watmough SJ; Shwe KH; Dasgupta R; Butt NM; Galvani D; Hoyle CF; Seale JR; Clark RE
    Leukemia; 2008 Oct; 22(10):1963-6. PubMed ID: 18754023
    [No Abstract]   [Full Text] [Related]  

  • 15. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
    Tauchi T; Oyashiki K
    Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
    [No Abstract]   [Full Text] [Related]  

  • 16. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
    Tunca Y; Güran S
    Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
    Peggs K; Mackinnon S
    N Engl J Med; 2003 Mar; 348(11):1048-50. PubMed ID: 12637616
    [No Abstract]   [Full Text] [Related]  

  • 18. Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
    Champlin RE; Kantarjian H
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):398-400. PubMed ID: 16258420
    [No Abstract]   [Full Text] [Related]  

  • 19. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imatinib--en epoch-making new drug against chronic myeloid leukemia].
    Lakartidningen; 2003 Jun; 100(26-27):2283. PubMed ID: 12872372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.